<DOC>
	<DOCNO>NCT00056264</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness infliximab ( Remicade ) patient Chronic Obstructive Pulmonary Disease ( COPD ) . Infliximab ( Remicade ) target specific proteins body 's immune system help control development inflammation help reduce painful disease .</brief_summary>
	<brief_title>A Study Safety Efficacy Infliximab ( Remicade ) Patients With COPD</brief_title>
	<detailed_description>Chronic Obstructive Pulmonary Disease ( COPD ) smoking-related inflammatory lung disease result reduce lung function , cause symptom problem breathe . COPD include chronic bronchitis emphysema . The symptom COPD cough , sputum ( phlegm ) production , breathlessness , wheeze . Advanced disease may also involve change appetite weight loss . The drug use study call Remicade√¢ , active component call infliximab . Infliximab bind block activity naturally occur substance body call tumor necrosis factor alpha TNFa , may associate inflammation decrease lung function.The purpose study evaluate safety effectiveness infliximab treatment patient symptoms moderate severe COPD.Patients receive infusion either placebo , 3 mg/kg infliximab 5mg/kg infliximab week 0 , 2 , 6 , 12 , 18 , 24.Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive infusion either placebo , 3 mg/kg infliximab 5mg/kg infliximab week 0 , 2 , 6 , 12 , 18 , 24 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients must moderate severe COPD Patients must least one episode COPDrelated symptom ( eg , cough , sputum production , shortness breath ) within 2 month prior screen Exclusion Criteria : Patients must asthma main component obstructive airway disease Patients must moderate severe exacerbation COPD within previous 1 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Remicade</keyword>
</DOC>